Evidence map›Paper›PMID 32926213›Full record

ArticleActa neuropathologica2020

Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity.

Leonille Schweizer, Felix Thierfelder, Christian Thomas, Patrick Soschinski, Abigail Suwala, Damian Stichel, Annika K Wefers, Lars Wessels, Martin Misch, Hee-Yeong Kim and 24 more

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. A 56-year-old woman with back pain and lower limbs weakness.Brain pathology (Zurich, Switzerland) · 2022
    Article
  12. Neuropathologic features of central nervous system hemangioblastoma.Journal of pathology and translational medicine · 2022
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 11 institutions in 1 country.

Leonille SchweizerDepartment of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany. leonille.schweizer@charite.de.ORCID 0000-0002-4649-2587
Felix ThierfelderDepartment of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Christian ThomasInstitute of Neuropathology, University Hospital Münster, Pottkamp 2, Münster, Germany.
Patrick SoschinskiInstitute of Neuropathology, University Hospital Münster, Pottkamp 2, Münster, Germany.
Abigail SuwalaDepartment of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Damian StichelDepartment of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Annika K WefersDepartment of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Lars WesselsDepartment of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Martin MischDepartment of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Hee-Yeong KimDepartment of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Ruben JödickeDepartment of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Daniel TeichmannDepartment of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
David KaulDepartment of Radiation Oncology and Radiotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.
Johannes KahnDepartment of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Michael BockmayrDepartment of Pathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin, Germany.
Martin HasselblattInstitute of Neuropathology, University Hospital Münster, Pottkamp 2, Münster, Germany.
Alexander YounsiDepartment of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.
Andreas UnterbergDepartment of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.
Bettina KnieDepartment of Neurosurgery, Vivantes Klinikum Im Friedrichshain, Berlin, Germany.
Jan WalterDepartment of Neurosurgery, Universitätsklinikum Jena, Jena, Germany.
Diaa Al SafatliDepartment of Neurosurgery, Universitätsklinikum Jena, Jena, Germany.
Sven-Axel MayDepartment of Neurosurgery, Klinikum Chemnitz, Chemnitz, Germany.
Andreas JödickeDepartment of Neurosurgery, Vivantes Klinikum Neukölln, Berlin, Germany.
Georgios NtouliasDepartment of Neurosurgery, Vivantes Klinikum Neukölln, Berlin, Germany.
Dag MoskoppDepartment of Neurosurgery, Vivantes Klinikum Im Friedrichshain, Berlin, Germany.
Peter VajkoczyDepartment of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Frank L HeppnerDepartment of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
David CapperDepartment of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Wolfgang HartmannDivision of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Christian HartmannDepartment of Neuropathology, Institute of Pathology, Hannover Medical School, Hannover, Germany.
Andreas von DeimlingDepartment of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
David E ReussDepartment of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Anne SchölerDepartment of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Arend KochDepartment of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
German Cancer Research Center · DECharité - Universitätsmedizin Berlin · DEUniversity Hospital Münster · DEHeidelberg University · DEHumboldt-Universität zu Berlin · DEJena University Hospital · DEKlinikum im Friedrichshain · DEVivantes Klinikum · DEKlinikum Chemnitz · DEMedizinische Hochschule Hannover · DEUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paragangliomas/pheochromocytomas are rare neuroendocrine tumors that arise from the adrenal gland or ganglia at various sites throughout the body. They display a remarkable diversity of driver alterations and are associated with germline mutations in up to 40% of the cases. Comprehensive molecular profiling of abdomino-thoracic paragangliomas revealed four molecularly defined and clinically relevant subtypes. Paragangliomas of the cauda equina region are considered to belong to one of the defined molecular subtypes, but a systematic molecular analysis has not yet been performed. In this study, we analyzed genome-wide DNA methylation profiles of 57 cauda equina paragangliomas and show that these tumors are epigenetically distinct from non-spinal paragangliomas and other tumors. In contrast to paragangliomas of other sites, chromosomal imbalances are widely lacking in cauda equina paragangliomas. Furthermore, RNA and DNA exome sequencing revealed that frequent genetic alterations found in non-spinal paragangliomas-including the prognostically relevant SDH mutations-are absent in cauda equina paragangliomas. Histologically, cauda equina paragangliomas show frequently gangliocytic differentiation and strong immunoreactivity to pan-cytokeratin and cytokeratin 18, which is not common in paragangliomas of other sites. None of our cases had a familial paraganglioma syndrome. Tumors rarely recurred (9%) or presented with multiple lesions within the spinal compartment (7%), but did not metastasize outside the CNS. In summary, we show that cauda equina paragangliomas represent a distinct, sporadic tumor entity defined by a unique clinical and morpho-molecular profile.

Indexed as

Cauda EquinaCentral Nervous System NeoplasmsDiagnosis, DifferentialFemaleGerm-Line MutationHumansMaleNeoplasm Recurrence, LocalNeuroendocrine TumorsParagangliomaPrognosisCauda equinaDNA methylationGATA3Head and neckParagangliomaSDHB

Identifiers

PMID32926213
PMCPMC7666289
OpenAlexW3086847472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.